journal article·2025-04-01Open access

Itaconate-loaded metal–organic framework (MOF) nanomedicine for the sustained treatment of intervertebral disk degeneration

Haixin Song, Jianhua Li, Qibin Zhang, Bingjie Zheng, Changsheng Li, Yiran Wang, Jian Chen, Junhui Liu, Tao Wu, Xiaotian Yang, Xueqian Kong, Fengdong Zhao

APL Materials· Volume 13· Issue 4

Abstract

Intervertebral disk degeneration (IVDD) is a major cause of spinal pathology and pain and can lead to disability in adults in severe cases. The medication against disk degeneration is limited due to the lack of therapeutic drugs and ineffective delivery of molecular drugs to target microenvironment. Itaconate is a tricarboxylic acid cycle secondary metabolite with inflammatory and oxidative stress modulating functions, which could alleviate disk degeneration. However, the lack of in vivo stability limits the potential application of itaconate against disk degeneration. In this study, we prepared metal–organic framework (MOF) nanocarrier drug loaded with itaconate that can respond to the acidic environment during disk degeneration. The results showed that the acidic microenvironment could induce sustained drug release from MOF@itaconate. In vitro cellular evaluation showed that MOF@itaconate has good cytocompatibility and significantly attenuates the inflammatory injury of nucleus pulposus cells. The nanocarrier activates the nuclear factor erythroid 2-related factor 2 (Nrf 2) anti-oxidative pathway and promotes the expression of nucleus pulposus extracellular matrix components. For the treatment of intervertebral disk degeneration on animal models, the MOF@itaconate nanocarrier was further coated with hyaluronic acid (HA) to boost the therapeutic effect. The administration of MOF@itaconate@HA in a rat disk degeneration model effectively delayed the degenerative process, suggesting that this technology may provide an effective controlled-release strategy for the treatment of IVDD.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Spine and Intervertebral Disc Pathology · Medical Imaging and Analysis · Anesthesia and Pain Management

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Rehabilitation, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University 1 , Hangzhou 310000, Zhejiang Province,

Key Laboratory of Musculoskeletal System Degeneration and Regeneration Translational Research of Zhejiang Province 2 , Hangzhou 310016, Zhejiang,

Department of Orthopedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine 3 , Hangzhou 310016, Zhejiang,

The First Affiliated Hospital of USTC AnHui Provincial Hospital 4 , Hefei 230000, Anhui,

Department of Chemistry, Zhejiang University 5 , Hangzhou 310016, Zhejiang,

Institute of Translational Medicine, Shanghai Jiao Tong University 6 , Shanghai 200233,

Funding

National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province · Medical and Health Research Project of Zhejiang Province

References (72)

Show source-provided references
1. An update of current therapeutic approach for intervertebral disc degeneration: A review article10.1016/j.amsu.2022.103619 ↗
3. Intervertebral disc degeneration and how it leads to low back pain10.1002/jsp2.1231 ↗
5. New strategies for the treatment of intervertebral disc degeneration: Cell, exosome, gene, and tissue engineering
6. New hope for treating intervertebral disc degeneration: Microsphere-based delivery system10.3389/fbioe.2022.933901 ↗
7. Innovative strategies for intervertebral disc regenerative medicine: From cell therapies to multiscale delivery systems10.1016/j.biotechadv.2017.11.009 ↗
8. Novel therapeutic strategies for degenerative disc disease: Review of cell biology and intervertebral disc cell therapy10.1177/2050312118761674 ↗
9. State of the union: A review of lumbar fusion indications and techniques for degenerative spine disease10.3171/2019.4.spine18915 ↗
10. Clinical practice guidelines for the noninvasive management of low back pain: A systematic review by the ontario protocol for traffic injury management (OPTIMa) collaboration10.1002/ejp.931 ↗
11. Sirtuins in intervertebral disc degeneration: Current understanding10.1186/s10020-024-00811-0 ↗
12. The emerging roles of nanocarrier drug delivery system in treatment of intervertebral disc degeneration-current knowledge, hot spots, challenges and future perspectives10.2147/dddt.s448807 ↗
13. Reviving intervertebral discs: Treating degeneration using advanced delivery systems10.1021/acs.molpharmaceut.3c00579 ↗
14. Construction of MOFs nanoplatform with pH-triggered release of protocatechuic acid for intervertebral disc degeneration therapy10.1016/j.matdes.2022.111493 ↗
15. Small molecule-based treatment approaches for intervertebral disc degeneration: Current options and future directions10.7150/thno.48987 ↗
16. Exploring the evolutionary roots and physiological function of itaconate10.1016/j.copbio.2020.11.005 ↗
17. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP110.1038/nature25986 ↗
18. Electrophilic properties of itaconate and derivatives regulate the IκBζ–ATF3 inflammatory axis10.1038/s41586-018-0052-z ↗
19. The nucleotide sensor ZBP1 and kinase RIPK3 induce the enzyme IRG1 to promote an antiviral metabolic state in neurons10.1016/j.immuni.2018.11.017 ↗
20. Octyl itaconate inhibits osteoclastogenesis by suppressing Hrd1 and activating Nrf2 signaling10.1096/fj.201900887rr ↗
21. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production10.1073/pnas.1218599110 ↗
22. Itaconic acid indicates cellular but not systemic immune system activation10.18632/oncotarget.25956 ↗
23. Itaconate modulates tricarboxylic acid and redox metabolism to mitigate reperfusion injury10.1016/j.molmet.2019.11.019 ↗
24. Mechanobiology of the human intervertebral disc: Systematic review of the literature and future perspectives10.3390/ijms24032728 ↗
25. Efficient oral insulin delivery enabled by transferrin-coated acid-resistant metal-organic framework nanoparticles10.1126/sciadv.abm4677 ↗
26. The chemistry and applications of metal-organic frameworks10.1126/science.1230444 ↗
27. Tailoring electron-rich fluorescent supramolecular organic frameworks for efficient capture and visual monitoring of iodine10.1002/adfm.202413694 ↗
28. Synthesis of pillar-layered metal–organic frameworks with variable backbones through sequence control10.1038/s41557-024-01717-4 ↗
29. Uniform single-crystal mesoporous metal–organic frameworks10.1038/s41557-024-01693-9 ↗
30. Metal–organic framework nanocarriers for drug delivery in biomedical applications10.1007/s40820-020-00423-3 ↗
31. MOF nanoparticles with encapsulated autophagy inhibitor in controlled drug delivery system for antitumor10.1021/acsami.7b16522 ↗
32. Metal–organic framework nanoparticles for ameliorating breast cancer-associated osteolysis10.1021/acs.nanolett.9b02916 ↗
33. Inherent anchorages in UiO-66 nanoparticles for efficient capture of alendronate and its mediated release10.1039/c4cc02570a ↗
34. Defect-assisted loading and docking conformations of pharmaceuticals in metal–organic frameworks10.1002/anie.202010231 ↗
35. Flexible porous metal-organic frameworks for a controlled drug delivery10.1021/ja710973k ↗
36. Metal-organic frameworks as efficient materials for drug delivery10.1002/anie.200601878 ↗
37. Nanoscale metal–organic frameworks for the Co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells10.1021/ja4098862 ↗
38. Organelle-specific triggered release of immunostimulatory oligonucleotides from intrinsically coordinated DNA–metal–organic frameworks with soluble exoskeleton10.1021/jacs.7b07895 ↗
39. Construction and sensing amplification of raspberry-shaped MOF@MOF10.1021/acs.inorgchem.1c04027 ↗
40. Tale of COF-on-MOF composites with structural regulation and stepwise luminescence enhancement10.1021/acsami.2c12606 ↗
41. Sparks from different worlds: Collaboration of MOFs and COFs10.1016/j.ccr.2020.213735 ↗
42. Unusual and highly tunable missing-linker defects in zirconium metal–organic framework UiO-66 and their important effects on gas adsorption10.1021/ja404514r ↗
43. Defect engineering: Tuning the porosity and composition of the metal–organic framework UiO-66 via modulated synthesis10.1021/acs.chemmater.6b00602 ↗
44. Solvent-derived defects suppress adsorption in MOF-7410.1038/s41467-023-38155-8 ↗
45. Molecular identification and quantification of defect sites in metal-organic frameworks with NMR probe molecules10.1038/s41467-022-32809-9 ↗
46. The instability of a stable metal–organic framework in amino acid solutions10.1007/s12274-022-4346-y ↗
47. Efficacy of hyaluronic acid on intervertebral disc inflammation: An in vitro study using notochordal cell lines and human disc cells10.1002/jor.24933 ↗
48. A pH/cellulase dual stimuli-responsive cellulose-coated metal–organic framework for eco-friendly fungicide delivery10.1016/j.cej.2023.142190 ↗
49. A general post-synthetic modification approach of amino-tagged metal–organic frameworks to access efficient catalysts for the Knoevenagel condensation reaction10.1039/c5ta00816f ↗
50. Bioenergetic dysfunction in the pathogenesis of intervertebral disc degeneration10.1016/j.phrs.2024.107119 ↗
51. Correlation between lactate levels and pH in discs of patients with lumbar rhizopathies10.1007/bf02146615 ↗
52. Intradiscal measurements of pH in patients with lumbar rhizopathies10.3109/17453676908989482 ↗
53. The cellular and molecular biology of the intervertebral disc: A clinician’s primer
54. Biomechanics in annulus fibrosus degeneration and regeneration10.1007/978-981-13-0950-2_21 ↗
55. The extracellular matrix: Structure, composition, age-related differences, tools for analysis and applications for tissue engineering10.1177/2041731414557112 ↗
56. SOX9 and the many facets of its regulation in the chondrocyte lineage10.1080/03008207.2016.1183667 ↗
57. The postnatal role of Sox9 in cartilage10.1002/jbmr.1696 ↗
58. SOX9: A stem cell transcriptional regulator of secreted niche signaling factors10.1101/gad.233247.113 ↗
59. ADAMTS: A novel family of extracellular matrix proteases10.1016/s1357-2725(00)00061-3 ↗
60. The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: A review
61. Oxidative stress in intervertebral disc degeneration: Molecular mechanisms, pathogenesis and treatment10.1111/cpr.13448 ↗
62. Aging and age related stresses: A senescence mechanism of intervertebral disc degeneration10.1016/j.joca.2015.09.019 ↗
63. Excessive reactive oxygen species are therapeutic targets for intervertebral disc degeneration10.1186/s13075-015-0834-8 ↗
64. Mitochondrial ROS promote macrophage pyroptosis by inducing GSDMD oxidation10.1093/jmcb/mjz020 ↗
65. Balanced basal-levels of ROS (redox-biology), and very-low-levels of pro-inflammatory cytokines (cold-inflammaging), as signaling molecules can prevent or slow-down overt-inflammaging, and the aging-associated decline of adaptive-homeostasis10.1016/j.exger.2022.112067 ↗
66. Anti-inflammatory mechanisms of suppressors of cytokine signaling target ROS via NRF-2/thioredoxin induction and inflammasome activation in macrophages10.5483/bmbrep.2020.53.12.161 ↗
67. Inflammation in intervertebral disc degeneration and regeneration10.1098/rsif.2014.1191 ↗
68. NF-κB signaling pathway in controlling intervertebral disk cell response to inflammatory and mechanical stressors10.2522/ptj.20150045 ↗
69. Effects of nuclear factor kappa B signaling pathway in human intervertebral disc degeneration10.1097/brs.0000000000000733 ↗
70. Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: An in situ zymographic and gene therapy study10.1186/ar2282 ↗
71. Inhibiting tumor necrosis factor-alpha at time of induced intervertebral disc injury limits long-term pain and degeneration in a rat model10.1002/jsp2.1014 ↗
72. Inhibiting IκB kinase-β downregulates inflammatory cytokines in injured discs and neuropeptides in dorsal root ganglia innervating injured discs in rats10.1097/brs.0000000000000374 ↗